The adipokine sFRP4 induces insulin resistance and lipogenesis in the liver

Publication date: Available online 20 July 2019Source: Biochimica et Biophysica Acta (BBA) - Molecular Basis of DiseaseAuthor(s): Tina Hörbelt, Birgit Knebel, Pia Fahlbusch, David Barbosa, Daniella Herzfeld de Wiza, Frederique Van de Velde, Yves Van Nieuwenhove, Bruno Lapauw, G. Hege Thoresen, Hadi Al-Hasani, Dirk Müller-Wieland, D. Margriet Ouwens, Jorg KotzkaAbstractSecreted frizzled-related protein (sFRP) 4 is an adipokine with increased expression in white adipose tissue from obese subjects with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). Yet, it is unknown whether sFRP4 action contributes to the development of these pathologies. Here, we determined whether sFRP4 expression in visceral fat associates with NAFLD and whether it directly interferes with insulin action and lipid and glucose metabolism in primary hepatocytes and myotubes. The association of sFRP4 with clinical measures was investigated in obese men with or without type 2 diabetes and with or without biopsy-proven NAFLD. To determine the impact of sFRP4 on metabolic parameters, primary human myotubes (hSkMC), or primary hepatocytes from metabolic healthy C57Bl6 and from systemic insulin-resistant mice, i.e. aP2-SREBP-1c, were used. Gene expression of sFRP4 in visceral fat from obese men associated with insulin sensitivity, triglycerides and NAFLD. In C57Bl6 hepatocytes, sFRP4 disturbed insulin action. Specifically, sFRP4 decreased the abundance of IRS1 and FoxO1 together with impair...
Source: Biochimica et Biophysica Acta (BBA) Molecular Basis of Disease - Category: Molecular Biology Source Type: research

Related Links:

no De Lorenzo Lifestyle interventions remain the first-line treatment for non-alcoholic fatty liver disease (NAFLD), even if the optimal alimentary regimen is still controversial. The interest in antioxidants has increased over time, and literature reports an inverse association between nutrients rich in antioxidants and the risk of mortality due to non-communicable diseases, including NAFLD. Mediterranean diet (MD) is a model characterized by main consumption of plant-based foods and fish and reduced consumption of meat and dairy products. MD represents the gold standard in preventive medicine, probably due to the har...
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Review Source Type: research
The objective of the present study was to investigate the association between hair and urine Al levels and obesity.MethodsA total of 206 lean and 205 obese non-occupationally exposed subjects (30-50 y.o.) were enrolled in the study. Hair and urine Al levels were assessed with ICP-MS. Laboratory quality control was performed using the certified reference materials of human hair, plasma, and urine.ResultsHair and urinary Al levels in obese subjects were significantly higher by 31% and 46% compared to the control levels, respectively. The presence of hypertension (41% cases), atherosclerosis (8%), type 2 diabetes melli...
Source: Journal of Trace Elements in Medicine and Biology - Category: Biochemistry Source Type: research
Abstract Non-Alcoholic Fatty Liver Disease (NAFLD), the most common liver disease, is characterized by accumulation of fat (>5% of the liver tissue), in the absence of alcohol abuse or other chronic liver diseases. Its prevalence is increasing because of obesity, metabolic syndrome or Type 2 Diabetes Mellitus (T2DM). NAFLD can cause liver inflammation and progress to Non-Alcoholic Steatohepatitis (NASH), fibrosis, cirrhosis or Hepatocellular Cancer (HCC). Nevertheless, Cardiovascular Disease (CVD) is the most common cause of morbidity and mortality in NAFLD/NASH patients. Current guidelines suggest the use of p...
Source: Current Vascular Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Vasc Pharmacol Source Type: research
The prevalence of non-alcoholic fatty liver disease (NAFLD) has been increasing rapidly and at the forefront of worldwide concern. Characterized by excessive fat accumulation in the liver, NAFLD regularly coexists with metabolic disorders, including type 2 diabetes, obesity, and cardiovascular disease. It has been well established that the presence of NAFLD increases the incidence of type 2 diabetes, while diabetes aggravates NAFLD to more severe forms of steatohepatitis, cirrhosis, and hepatocellular carcinoma. However, recent progress on the genotype/phenotype relationships in NAFLD patients indicates the development of ...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 25 July 2019Source: Journal of Clinical and Experimental HepatologyAuthor(s): Raseen Tariq, Page Axley, Ashwani SingalAbstractNon-Alcoholic Fatty Liver Disease (NAFLD) is now the leading cause of chronic liver disease worldwide with a strong association with metabolic syndrome. NAFLD is truly a systemic disease and is associated with a plethora of extra-hepatic manifestations or comorbidities. These are either related to secondary effects of associated obesity or from pathophysiological effects of insulin resistance in NAFLD. Three most common causes of increased morbidity and mortality a...
Source: Journal of Clinical and Experimental Hepatology - Category: Gastroenterology Source Type: research
Publication date: Available online 24 July 2019Source: Archives of Cardiovascular Diseases SupplementsAuthor(s): Imen Sebai, Ibtissem Oueslati, Emna Talbi, Emna El Feleh, Wafa Grira, Meriem Yazidi, Fatma Chaker, Melika ChihaouiAimsNon-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in type 2 diabetes mellitus (T2DM). In addition to its liver complications, it is associated with increased cardiovascular risk. The aim of our work was to assess the relationship between NAFLD and cardiovascular disease risk (CVDR) in a group of patients with T2DM.MethodsThis was a cross-sectional study conducted ...
Source: Archives of Cardiovascular Diseases Supplements - Category: Cardiology Source Type: research
Publication date: Available online 22 July 2019Source: The Lancet Diabetes &EndocrinologyAuthor(s): Oana P Zaharia, Klaus Strassburger, Alexander Strom, Gidon J Bönhof, Yanislava Karusheva, Sofia Antoniou, Kálmán Bódis, Daniel F Markgraf, Volker Burkart, Karsten Müssig, Jong-Hee Hwang, Olof Asplund, Leif Groop, Emma Ahlqvist, Jochen Seissler, Peter Nawroth, Stefan Kopf, Sebastian M Schmid, Michael Stumvoll, Andreas F H PfeifferSummaryBackgroundCluster analyses have proposed different diabetes phenotypes using age, BMI, glycaemia, homoeostasis model estimates, and islet autoantibodies. We ...
Source: The Lancet Diabetes and Endocrinology - Category: Endocrinology Source Type: research
Conclusion: The presence of the PNPLA3 G allele is associated with a risk of NAFLD. Our study shows that subjects with variant PNPLA3 are not only at increased risk for the development and progression of NAFLD, but also have increased insulin resistance. PMID: 31304703 [PubMed - in process]
Source: Journal of the Association of Physicians of India - Category: General Medicine Tags: J Assoc Physicians India Source Type: research
With the growing prevalence of childhood obesity, pediatric non-alcoholic fatty liver disease (NAFLD) has emerged as the most common chronic liver disease in children and adolescents in Western countries.1 –3 NAFLD is a spectrum of progressive liver disease that encompasses simple steatosis, non-alcoholic steatohepatitis (NASH), advanced fibrosis and, ultimately, cirrhosis.3,4 Compelling evidence indicates that NAFLD also has serious health consequences outside of the liver and is strongly associate d with an increased risk of cardiovascular disease and abnormal glucose tolerance (prediabetes and type 2 diabetes).
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
With the growing prevalence of childhood obesity, pediatric non-alcoholic fatty liver disease (NAFLD) has emerged as the most common chronic liver disease in children and adolescents in Western countries [1 –3]. NAFLD is a spectrum of progressive liver disease that encompasses simple steatosis, non-alcoholic steatohepatitis (NASH), advanced fibrosis and, ultimately, cirrhosis [3,4]. Compelling evidence indicates that NAFLD also has serious health consequences outside of the liver and is strongly asso ciated with an increased risk of cardiovascular disease and abnormal glucose tolerance (prediabetes and type 2 diabetes) [5–7].
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
More News: Alcoholism | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Fatty Liver Disease (FLD) | Genetics | Insulin | Liver | Liver Disease | Molecular Biology | Non-alcoholic Fatty Liver Diseases (NAFLD) | Obesity | Urology & Nephrology